In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies-Reference-Cited by-同舟云学术

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

Published:2009-11-25 Issue:3 Volume:38 Page:448-458
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Wang Lifei,Zhang Donglu,Raghavan Nirmala,Yao Ming,Ma Li,Frost Charles A.,Maxwell Brad D.,Chen Shiang-yuan,He Kan,Goosen Theunis C.,Griffith W. Humphreys,Grossman Scott J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference33 articles.

1. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome

2. THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

3. Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

4. In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective

5. Analysis of CYP mRNA expression by branched DNA technology;Czerwinski;Methods Enzymol,2002

Cited by 219 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of the antitumor drugs adagrasib and asciminib on apixaban metabolism in vitro and in vivo;Chemico-Biological Interactions;2024-08

2. Clinical Implications of Co‐administering Apixaban with Key Interacting Medications;Clinical Pharmacology in Drug Development;2024-07-24

3. Development of radioiodine-labeled mequitazine for evaluation of hepatic CYP2D activity;Frontiers in Pharmacology;2024-06-19

4. The impact of ABCB1, CYP3A4 and CYP3A5 gene polymorphisms on apixaban trough concentration and bleeding risk in patients with atrial fibrillation;Drug Metabolism and Personalized Therapy;2024-06-01

5. Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations;Clinical and Translational Science;2024-05